Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Sarcoma 2Rectal Neoplasms 1Oligodendroglioma 1Meningioma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Gliosarcoma 1Glioma 1Glioblastoma 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Brain Neoplasms 1Astrocytoma 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Oxaliplatin 21Capecitabine 17Fluorouracil 15Irinotecan 11Radiotherapy 10Leucovorin 8Cetuximab 6Bevacizumab 6Gemcitabine 5oblimersen 3fludarabine 3aldesleukin 3Nivolumab 3Erlotinib Hydrochloride 3Cyclophosphamide 3labetuzumab 2dehydroftorafur 2conatumumab 2Tomography, X-Ray Computed 2Receptor Protein-Tyrosine Kinases 2Radiation 2Panitumumab 2Neoadjuvant Therapy 2Magnetic Resonance Imaging 2Interleukin-2 2Gefitinib 2Electrocardiography 2Diphenhydramine 25,10-methylenetetrahydrofolic acid 2tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Rectal Neoplasms × Semaxinib × Clear all
NCT00005818 2013-01-23

SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
68 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡